



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Finlee

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
PSUSA/10084 /202405	Periodic Safety Update EU Single assessment - dabrafenib	30/01/2025	04/04/2025	SmPC	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10084/202405.
WS/2762	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	20/03/2025		SmPC and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
IAIN/0011	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	03/12/2024	04/04/2025	Annex II and PL	
IG/1769	C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority	07/08/2024	21/02/2025	SmPC and PL	
WS/2693	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to add photosensitivity to the list of adverse drug reactions (ADRs) with frequency Common respectively and to update efficacy and safety information on paediatric population based on final results from study CDRB436G2201; this is a phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG). The Package</p>	18/07/2024	21/02/2025	SmPC and PL	<p>SmPC new text:</p> <p>Low grade glioma (LGG): At the time of the final analysis (median duration of follow-up: 39.0 months), the ORR based on independent review was 54.8% in the D+T arm and 16.2% in the C+V arm with an odds ratio of 6.26. The analysis also confirmed improved PFS over chemotherapy based on independent review with an estimated 64% risk reduction in progression/death (hazard ratio 0.36). The median PFS was 24.9 months in the D+T arm and 7.2 months in the C+V arm. No additional deaths were reported in either arm at the time of the final analysis.</p> <p>High grade glioma (HGG): At the time of the final analysis (median duration of follow-up: 45.2 months), the ORR based on independent review was 56.1% (23/41), (95% CI: 39.7, 71.5): CR in 14 patients (34.1%) and PR in 9</p>

	<p>Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				<p>patients (22.0%). The median duration of response (DoR) was 27.4 months (95% CI: 9.2, NE).</p> <p>For more information, please refer to the Summary of Product Characteristics.</p>
WS/2671	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.8 of the SmPC in order to add 'Atrioventricular (AV) block' with an uncommon frequency for Finlee and Spexotras and common frequency for Tafinlar to the list of adverse drug reactions (ADRs), following the PRAC recommendation in the PSUR for Mekinist (PSUSA/00010262/202305). The Package Leaflet is updated accordingly.</p> <p>C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH</p>	16/05/2024	21/02/2025	SmPC and PL	<p>Not applicable</p> <p>For more information, please refer to the Summary of Product Characteristics.</p>
WS/2612	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.4 and 4.8 of the SmPC in order</p>	25/04/2024	21/02/2025	SmPC and PL	<p>SmPC new text</p> <p>Tumour lysis syndrome</p> <p>The occurrence of TLS, which may be fatal, has been associated with the use of dabrafenib in combination with trametinib (see section 4.8). Risk factors for TLS include</p>

	<p>to add a new warning on Tumour lysis syndrome and add Tumour lysis syndrome to the list of adverse drug reactions (ADRs) with frequency Not known based on the review of MAH global database, clinical trials database and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3 and to introduce editorial changes.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				<p>high tumour burden, pre existing chronic renal insufficiency, oliguria, dehydration, hypotension and acidic urine. Patients with risk factors for TLS should be closely monitored and prophylactic hydration should be considered. TLS should be treated promptly, as clinically indicated. For more information, please refer to the Summary of Product Characteristics.</p>
WS/2670	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p>	11/04/2024	21/02/2025	SmPC and PL	
IAIN/0006	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	13/03/2024	n/a		
IAIN/0002	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	22/12/2023	n/a		
IAIN/0001/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name</p>	22/12/2023	21/02/2025	Annex II and PL	

	<p>and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p>				
--	--	--	--	--	--